金吾财讯 | 默沙东(MRK)盘前股价拉升，暂报80.37美元，涨1.77%。消息面上，公司今天宣布了三项 3 期临床试验中前两项的积极顶线结果，这些试验评估了恩利西肽癸酸酯的安全性和有效性。恩利西肽是一种在研口服前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型 (PCSK9) 抑制剂，正在评估其用于治疗正在接受降脂疗法（包括至少一种他汀类药物）的高脂血症成人患者。CORALreef HeFH 和 CORALreef AddOn 试验成功达到了其主要终点和所有关键次要终点，表明与安慰剂（CORALreef HeFH）和其他口服非他汀类药物疗法（CORALreef AddOn）相比，恩利西肽在降低低密度脂蛋白胆固醇 (LDL-C) 方面具有统计学上和临床上显著的更高水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.